AK03, a new recombinant fibrinogenase prevents abdominal adhesions in a rat model without systemic side effects

The results of this study indicate that the new recombinant fibrinogenase AK03 effectively prevents peritoneal adhesions without causing side effects, notably systemic fibrinogen depletion, bleeding, or impaired wound repair. Due to these results, future clinical studies may be promising.